Patents Examined by Susanna Moore
  • Patent number: 12291534
    Abstract: The present invention relates to a compound of formula I or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an ester, an optical isomer or a prodrug thereof, a pharmaceutical composition comprising the compound of formula I, and use of the compound, as a Bruton's tyrosine kinase inhibitor with high selectivity for BTK(C481S) mutant, in the manufacture of a medicament for preventing or treating a heteroimmune disease, an autoimmune disease or a cancer.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: May 6, 2025
    Assignee: TRANSTHERA SCIENCES (NANJING), INC.
    Inventor: Rongyao Chen
  • Patent number: 12286429
    Abstract: The present invention is directed to 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof The present invention is also directed to pharmaceutical compositions containing such compounds and the use of such compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: April 29, 2025
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Mark J. Macielag
  • Patent number: 12285488
    Abstract: Disclosed are stable dosage forms for oral administration of active pharmaceutical ingredients in which any unpleasant taste sensation, caused by release of the active pharmaceutical ingredient and/or of the excipients in the oral and pharyngeal cavity of the patient, is masked by the use of theobromine-free cocoa.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: April 29, 2025
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Thomas Hille, Gabriel Wauer, Frank Seibertz
  • Patent number: 12286440
    Abstract: An object of the present invention is to provide a compound and a pharmaceutical composition which exhibit strong antibacterial activity against Gram-negative bacteria and drug-resistant Gram-negative bacteria. A compound represented by General Formula [1](the reference signs in Formula have the same definitions as those described in the present specification) or a salt thereof has strong antibacterial activity against Gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant Gram-negative bacteria including multidrug-resistant Pseudomonas aeruginosa, and the pharmaceutical composition containing the compound or a salt thereof is useful as an antibacterial agent.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: April 29, 2025
    Assignee: FUJIFILM Corporation
    Inventors: Muneo Shoji, Kentaro Furuya, Kei Matsuura, Tomofumi Nakae
  • Patent number: 12281073
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: July 5, 2023
    Date of Patent: April 22, 2025
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Norihito Tokunaga, Mariko Hirozane
  • Patent number: 12275739
    Abstract: Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific inhibitors of menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the menin-MLL inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin-MLL interaction.
    Type: Grant
    Filed: November 6, 2023
    Date of Patent: April 15, 2025
    Assignee: BIOMEA FUSION, INC.
    Inventors: Thomas Butler, Jim Palmer, Ravi Upasani, Matthew Welsch, Sridhar Vempati, Brendan Kelly, Edward Painter
  • Patent number: 12275728
    Abstract: Described herein are compounds represented by formulas (IA) or (IB) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.
    Type: Grant
    Filed: May 24, 2024
    Date of Patent: April 15, 2025
    Assignee: BIOGEN MA INC.
    Inventors: Nathan Genung, Kevin M. Guckian, Jeffrey Vessels, Lei Zhang, Ryan Gianatassio, Edward Yin Shiang Lin, Zhili Xin
  • Patent number: 12269828
    Abstract: Described herein are cyclic amide-containing pyridyl-xanthines of formula I and pharmaceutical compositions thereof that are useful as antagonists of A2B adenosine receptors.
    Type: Grant
    Filed: October 16, 2023
    Date of Patent: April 8, 2025
    Assignee: Adovate, LLC
    Inventor: Robert D Thompson
  • Patent number: 12268667
    Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 8, 2025
    Assignee: Incyte Corporation
    Inventors: Paul Smith, Kurt Andrew Brown
  • Patent number: 12258340
    Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising the same. The compounds and compositions are useful as modulators of monoacylglycerol lipase (MAGL). Furthermore, the compounds and compositions are useful for the treatment of pain.
    Type: Grant
    Filed: March 16, 2023
    Date of Patent: March 25, 2025
    Assignee: H. LUNDBECK A/S
    Inventors: Cheryl A. Grice, John J. M. Wiener, Olivia D. Weber, Katharine K. Duncan
  • Patent number: 12258354
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: March 25, 2025
    Assignee: IDEAYA Biosciences, Inc.
    Inventors: Muzaffar Alam, Hilary Plake Beck, Michael Patrick Dillon, Marcos Gonzalez-Lopez, James Clifford Sutton, Jr.
  • Patent number: 12258370
    Abstract: The present disclosure relates to Betulastatin compounds, pharmaceutical compositions and kits comprising such compounds, and methods for using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 8, 2023
    Date of Patent: March 25, 2025
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: George R. Pettit, Noeleen Melody
  • Patent number: 12252495
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: August 4, 2023
    Date of Patent: March 18, 2025
    Assignee: ASTRAZENECA AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • Patent number: 12252460
    Abstract: The present invention relates to a novel crystal modification of N-(aminoiminomethyl)-2-aminoacetic acid, crystal mixtures, and a process for preparing said crystal modification and said crystal mixtures.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: March 18, 2025
    Assignee: Alzchem Trostberg GmbH
    Inventors: Thomas Güthner, Franz Thalhammer, Jürgen Sans
  • Patent number: 12247029
    Abstract: Compounds of the following formula: having defined substituents. The compounds can inhibit class II phosphoinositide 3-kinase (PI3K) signaling and are useful for the treatment of a medical condition associated with defective PI3K signaling, such as myopathy, cancer, diabetes, thrombosis or cardiovascular disease.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: March 11, 2025
    Assignee: Forschungsverbund Berlin e.V.
    Inventors: Wen-Ting Lo, Hassane Belabed, Volker Haucke, Marc Nazare, Murat Kucukdisli
  • Patent number: 12240867
    Abstract: Described herein are compounds of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: March 4, 2025
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Abdelghani Abe Achab, Matthew L. Childers, Jared N. Cumming, Symon Gathiaka, Charles A. Lesburg, Derun Li, Min Lu, Matthew J. Mitcheltree, Anandan Palani, Rachel L. Palte, Hongjun Zhang
  • Patent number: 12239632
    Abstract: Provided are allyl tryptamines, such as asymmetric allyl tryptamines. In some embodiments, such compounds modulate the activity of monoamine receptors and/or monoamine transporters. Also provided are methods for the preparation of allyl tryptamines and pharmaceutical compositions thereof. Methods of using the allyl tryptamines, alone or in combination with other therapeutic agents, are provided. In some embodiments, allyl tryptamines are used to treat CNS disorders, such as mental health conditions and neurodegenerative disorders, or are used for the improvement of mental health or functioning.
    Type: Grant
    Filed: March 4, 2024
    Date of Patent: March 4, 2025
    Assignee: Alexander Shulgin Research Institute, Inc.
    Inventors: Paul F. Daley, Nicholas V. Cozzi, Wyeth B. Callaway
  • Patent number: 12240829
    Abstract: The disclosure relates to Prostnglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, epilepsy, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 4, 2025
    Assignee: Emory University
    Inventors: Thota Ganesh, Raymond J. Dingledine, Radhika Amaradahi, Shabber Mohammed
  • Patent number: 12227521
    Abstract: The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: February 18, 2025
    Assignee: Nxera Pharma UK Limited
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield
  • Patent number: 12227520
    Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: February 18, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang